860409C

9-PAHSA-d9

Avanti Research^™ - A Croda Brand 860409C

• 同義詞: 9-[((13,13,14,14,15,15,16,16,16-d9)palmitoyl)hydroxy]-stearic acid
• 經驗公式（希爾表示法）: C₃₄H₅₇D₉O₄
• CAS號碼: 1809222-43-2
• 分子量：: 547.94
• 分類程式碼代碼: 12352211
• NACRES: NA.25

屬性

• 化驗: >99% (TLC)
• 形狀: liquid
• 包裝: pkg of 1 × 1 mL (860409C-1mg); pkg of 1 × 1 mL (860409C-500ug)
• 製造商／商標名: Avanti Research^™ - A Croda Brand 860409C
• 濃度: 0.5 mg/mL (860409C-500ug); 1 mg/mL (860409C-1mg)
• 運輸包裝: dry ice
• 儲存溫度: −20°C
• SMILES 字串: CCCCCCCCCC(OC(CCCCCCCCCCCC([2H])(C([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])[2H])=O)CCCCCCCC(O)=O

描述

一般說明

9-PAHSA-d9 9-[((13,13,14,14,15,15,16,16,16-d9)palmitoyl)hydroxy]-stearic acid is a deuterated palmitoyl hydroxy-stearic acid wherein the nine protons of palmitoyl are replaced by deuterium. Palmitic acid-9-hydroxy-stearic acid (9-PAHSA) is the most abundantly found fatty acid ester of hydroxy fatty acids (FAHFA).

PAHSA levels correlate highly with insulin sensitivity and are reduced in adipose tissue and serum of insulin-resistant humans. In adipocytes, PAHSAs signal through GPR120 to enhance insulin-stimulated glucose uptake. Thus, FAHFAs are endogenous lipids with the potential to treat type 2 diabetes. Avanti has obtained a license from the patent holder to manufacture these products for research use.

包裝

5 mL Clear Glass Sealed Ampule (860409C-1mg)

5 mL Clear Glass Sealed Ampule (860409C-500ug)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

安全資訊

• 象形圖: GHS06,GHS08
• 訊號詞: Danger
• 危險聲明: H302,H315,H319,H331,H336,H351,H361d,H372
• 防範說明: P202 - P301 + P312 - P302 + P352 - P304 + P340 + P311 - P305 + P351 + P338 - P308 + P313
• 危險分類: Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3
• 標靶器官: Liver,Kidney, Respiratory system
• 儲存類別代碼: 6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: does not flash
• 閃點（°C）: does not flash